News, guides, and explainers that feed the reference pages rather than replace them. Each post cites its sources and links to the canonical peptide, condition, comparison, or legal page for the full record.
57 posts. RSS feed. Posts marked draft are pending editorial review.
Q&A5 min readDraft
CJC-1295 side effects in small human studies included injection site reactions, headache, flushing, diarrhea, and a faster heart rate. It has no FDA approval and no lawful compounding path.
Explainer5 min readDraft
Sermorelin signals the pituitary to release growth hormone; HGH (somatropin) is the hormone itself. Only somatropin is FDA approved today, and anti-aging use of either is off-label.
Explainer5 min readDraft
Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions.
Explainer8 min readDraft
FDA-approved peptide injections have documented side effects on their labels. Compounded and research-only peptides add unknowns: sterility, identity, dose accuracy, and contamination.
Explainer7 min readDraft
Minoxidil side effects differ by form: scalp irritation and unwanted facial hair with topical use, body hair and fluid retention with oral use. Plus shedding, pregnancy, and the danger to cats.
Explainer7 min readDraft
Low-dose oral minoxidil is an off-label hair loss treatment. What the FDA label for the blood pressure tablet says, what the hair loss trials found, and the side effects they reported.
Explainer7 min readDraft
Sildenafil is the active ingredient in Viagra. How generic sildenafil compares, why 20 mg tablets are labeled for pulmonary hypertension, the label side effects, and the nitrate contraindication.
Explainer6 min readDraft
5-amino-1MQ reduced fat mass in obese mice, but no human study of any kind has been published. What the mouse studies found, capsules vs injection, side effects, and legal status.
Explainer6 min readDraft
BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.
Explainer7 min readDraft
BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.
Study breakdown6 min readDraft
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
Explainer6 min readDraft
No published study has given BPC-157 as a nasal spray to animals or people. What the one nose-related rat study tested, what a nasal peptide must prove, and its legal status.
Guide7 min readDraft
The tirzepatide shortage ended in December 2024 and routine compounded copies ended in 2025. What is still lawful, what it cost, FDA safety warnings, and how to check a pharmacy.
Explainer6 min readDraft
Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil.
Explainer6 min readDraft
No FDA-approved GLP-1 patch exists. Here is why GLP-1 drugs cannot pass through skin from a sticker, what patch ingredients have been tested by mouth, and how to read patch reviews.
Q&A7 min readDraft
Tesamorelin raised lean body mass about 1.2 kg in HIV trials and slightly increased trunk muscle area, but no trial tested strength or muscle growth, and it is prohibited in sport.
Study breakdown6 min readDraft
Most epitalon human data come from one research group and used the pineal extract Epithalamin, not synthetic epitalon. What each study measured, plus the melatonin, telomerase, and cancer questions.
Explainer6 min readDraft
Berberine, fiber, and probiotics sold as GLP-1 boosters are not GLP-1 drugs. Here is the human evidence for each ingredient, graded, and how it compares with semaglutide and tirzepatide.
Guide8 min readDraft
Which peptides a licensed prescriber can lawfully write for today, which are waiting on an FDA rule, how telehealth rules work, and the red flags that mean a product is not a prescription at all.
Guide7 min readDraft
Retatrutide is not approved, so a clinical trial is the only lawful way to get it. How to search ClinicalTrials.gov, how expanded access works, and why online and compounded sources are unlawful.
Explainer7 min readDraft
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
Explainer6 min readDraft
Melanotan 1 is afamelanotide, approved only as an implant for a rare light sensitivity disease. What the tanning and approval trials measured, what happens to moles, and why tanning use is unapproved.
Explainer6 min readDraft
Melanotan 2 before and after photos show a tan. Early trials measured it in a few men; case reports since document new moles, melanoma, priapism and FDA safety concerns.
Explainer7 min readDraft
No trial has tested microdosing semaglutide or tirzepatide. What the labels say about dose steps and why they exist, FDA's dosing-error warnings, and what to ask a prescriber.
Explainer6 min readDraft
MOTS-c prevented diet-induced obesity in mice, but no human trial has tested it for weight loss. What the mouse data show, what human blood studies found, and where it stands legally.
Explainer6 min readDraft
What N-terminal acetylation and C-terminal amidation are claimed to change in semax and selank, what the lab studies actually found, and why no human study has tested either modified version.
Explainer7 min readDraft
Oral BPC-157 worked in rat gut, ligament, and fistula studies. No study has measured how much an oral capsule absorbs in people, and the two registered oral studies have posted no results.
Explainer7 min readDraft
Measured peptide before and after results: GLP-1 weight change, tesamorelin visceral fat, and regain after stopping, compared with Glow, GHK-Cu, BPC-157, and Wolverine claims.
Ranked by evidence8 min readDraft
No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.
Ranked by evidence7 min readDraft
hCG, GLP-1 drugs, teriparatide, and tesamorelin have human trials and a lawful route. PT-141 is off-label for men, and kisspeptin and melanotan II have no lawful path. Ranking, legality, and WADA.
Ranked by evidence8 min readDraft
MK-677, sermorelin, tesamorelin, CJC-1295, IGF-1 LR3, and more ranked by human evidence. None is approved for muscle growth, and all ten are banned in tested sport.
Ranked by evidence10 min readDraft
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Ranked by evidence7 min readDraft
GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.
Study breakdown6 min readDraft
What retatrutide trials measured: 24.2% mean weight loss at 48 weeks in phase 2, up to 28.3% at 80 weeks in phase 3, and what happened to fat, waist size, and blood sugar.
Explainer6 min readDraft
What retatrutide trials measured besides weight: liver fat, HbA1c, blood pressure, lipids, fat mass, and knee pain. What is proven, what is post hoc, and what is still unknown.
Explainer7 min readDraft
Nausea, diarrhea, dysesthesia, heart rate, and dropouts in the retatrutide trials, with placebo rates. What the data say about safety, and what is still unknown.
Explainer6 min readDraft
What the intranasal selank studies measured, whether the route matters, and what is known about semax and selank nasal spray together: no trial has tested the combination.
Q&A6 min readDraft
Does selank cause withdrawal? What studies measured on dependence, how it compares with benzodiazepines, the rodent alcohol and opioid withdrawal studies, and the untested alcohol interaction.
Explainer7 min readDraft
Semax was developed in Russia as nasal drops. What the intranasal stroke and imaging studies measured, how nasal and injected data compare, and what the July 2026 PCAC vote means.
Explainer6 min readDraft
TB-500 is not the same molecule as thymosin beta-4. What each one is, which has human data, what is known about capsules and sprays, and what the evidence says about cancer.
Explainer8 min readDraft
Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.
Guide8 min readDraft
How to get tesamorelin legally: who qualifies for Egrifta WR on label, how off-label prescribing works, why compounded tesamorelin is not lawful, what a visit should check, and cost.
Explainer7 min readDraft
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.
Guide7 min readDraft
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and US compounding has no lawful basis. What that means for access, forms, and thymalin.
Explainer6 min readDraft
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared.
Explainer9 min readDraft
Peptide therapy means three different things: FDA-approved drugs, compounded prescriptions, and research-only products. Here is how to tell them apart, what the evidence shows, and what it costs.
Guide8 min readDraft
Yes in every state, but the rules for the visit, the prescriber's license, and the pharmacy differ. How state telehealth law shapes GLP-1 access, with ten state examples.
Ranked by evidence4 min readDraft
Nausea tops the list, but the label warnings matter more. Side effects of semaglutide and tirzepatide ranked by how often they occurred in the trials, with placebo rates for context.
Guide5 min readDraft
Compounded semaglutide and tirzepatide are now limited to documented patient-specific needs. Here is how the lawful path works, how to check a pharmacy, and what the branded alternatives cost.
Explainer5 min readDraft
A practical checklist for judging peptide research: who was studied, how it was designed, what was measured, and whether it was replicated. Worked through with real studies.
News5 min readDraft
FDA's compounding advisory committee backed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list and rejected DSIP. Here is what the vote does and does not do.
Ranked by evidence4 min readDraft
BPC-157, TB-500, GHK-Cu, PEG-MGF, and IGF-1 LR3 ranked by our evidence grades. None has a published human tendon trial. Here is the ranking, the reasoning, and what does have human data.
Explainer5 min readDraft
Five phase 3 readouts, one peer-reviewed paper, and no approval yet. What the retatrutide trials have shown, what is still pending, and why no one can lawfully sell it today.
Study breakdown4 min readDraft
The first head-to-head obesity trial of tirzepatide and semaglutide found a 20.2% vs 13.7% weight loss gap at 72 weeks. What it tested, what it did not, and what it means for access.
Q&A4 min readDraft
Semaglutide now comes as a daily tablet and a weekly injection for weight management. We compare the trials, the label differences, and what each costs to get.
Explainer6 min readDraft
Peptides are short chains of amino acids. Some are FDA approved medicines, some are compounded, and many are unapproved research chemicals. Here is how to tell them apart.
Trends and data5 min readDraft
Compounded semaglutide went from a shortage workaround to a narrow, patient-specific exception. Here is the timeline, what FDA found, and what access looks like in 2026.
Educational reference, not medical advice. Read the full disclaimer and talk to a licensed provider before starting, stopping, or combining any treatment.